Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial
Shahneen Sandhu, Joaquı́n Mateo, Susana Miranda, Suzanne Carreira, Shreyans K. Jain, Christy Ralph, Andrew Protheroe, S. Perwez Hussain, Robin L. Jones, Tony Elliot, Ursula McGovern, Alexa Gillman, Claire Paulding, Helen Mossop, Núria Porta, Diletta Bianchini, Zafeiris Zafeiriou, Gunther Boysen, DN Rodrigues, Penny Flohr, George Seed, J Goodal, I. Figueiredo, Raquel Pérez-López, Nina Tunariu, A. Omlin, Roberta Ferraldeschi, LP Kunju, Rosalind A. Eeles, G. Attard, Dan R. Robinson, Arul Chinnaiyan, Emma Hall, Johann S. de Bono (2015). Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial.
Article276 days agoAssessing the impact of total quality management and organisational culture on multiple outcomes of care for coronary artery bypass graft surgery patients
Stephen M Shortell, Robin L. Jones, Alfred Rademaker, Robin R. Gillies, David Dranove, Edward J. Hughes, Peter P. Budetti, Katherine J. Reynolds, Cheng-Fang Huang (2010). Assessing the impact of total quality management and organisational culture on multiple outcomes of care for coronary artery bypass graft surgery patientsDOI: https://doi.org/10.4324/9780203337394_chapter_22,
Chapter in a book85 days agoUpdated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C. Heinrich, Jean Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Robin L. Jones, Yoon‐Koo Kang, Albiruni R. Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, Kjetil Boye, David Goldstein, César Sánchez, Brittany L. Siontis, P. H. Cox, Erika Davis, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE. , 43(20), DOI: https://doi.org/10.1200/jco-24-02818.
Article21 days agoINSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.
Michael C. Heinrich, Jean Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, Hans Gelderblom, John Zalcberg, William M. Reichmann, Kam Sprott, Matthew L. Sherman, Sebastian Bauer, Suzanne George (2025). INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with <i>KIT</i> exon 11 + 17/18 mutations.. , 43(4_suppl), DOI: https://doi.org/10.1200/jco.2025.43.4_suppl.tps848.
Article21 days agoGuidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment
César Serrano, Sebastian Bauer, Jean Yves Blay, Paolo G. Casali, Carlo María Cicala, Angelo Paolo Dei Tos, Antonia Digklia, Hans Gelderblom, Antoine Italiano, Robin L. Jones, Bernd Kasper, Anastasios Kyriazoglou, François Le Loarer, Javier Martín‐Broto, Andrea Napolitano, Piotr Rutkowski, Silvia Stacchiotti, William D. Tap, David J. Thomas, Khin Thway, Claudia Valverde, Winette T.A. van der Graaf, Eva Wardelmann, Judith V.M.G. Bovée (2025). Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment. , 11(12), DOI: https://doi.org/10.1001/jamaoncol.2025.3608.
Article21 days ago